Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents

Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia

Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892

Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine

Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156

Comorbidity of Mental Disorders With Alcohol and Other Drug Abuse: Results From the Epidemiologic Catchment Area (ECA) Study

Regier, D. A. (1990) · JAMA · doi:10.1001/jama.1990.03450190043026 · Cited by 3,962

Oxytocin increases trust in humans

Kosfeld, M., Heinrichs, M., Zak, P. J., Fischbacher, U., & Fehr, E. (2005) · Nature · doi:10.1038/nature03701 · Cited by 3,690

What are the functional consequences of neurocognitive deficits in schizophrenia?

(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516

Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses

Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330

A review of central 5-HT receptors and their function

Barnes, N. M., & Sharp, T. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00010-6 · Cited by 3,161

Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the ‘‘right stuff’’?

Green, M. F., Kern, R. S., Braff, D. L., & Mintz, J. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033430 · Cited by 2,999

Recent advances in the phencyclidine model of schizophrenia

(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904

Effect of COMT Val 108/158 Met genotype on frontal lobe function and risk for schizophrenia

Egan, M. F., Goldberg, T. E., Kolachana, B. S., Callicott, J. H., Mazzanti, C. M., Straub, R. E., Goldman, D., & Weinberger, D. R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.111134598 · Cited by 2,381

Cortical inhibitory neurons and schizophrenia

Lewis, D. A., Hashimoto, T., & Volk, D. W. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1648 · Cited by 2,297

Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.

Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61162-3 · Cited by 2,224

Dopamine in schizophrenia: a review and reconceptualization

(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.11.1474 · Cited by 2,018

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930

Rethinking schizophrenia

Insel, T. R. (2010) · Nature · doi:10.1038/nature09552 · Cited by 1,783

Modulation of memory fields by dopamine Dl receptors in prefrontal cortex

Williams, G. V., & Goldman-Rakic, P. S. (1995) · Nature · doi:10.1038/376572a0 · Cited by 1,593

Neuroendocrine perspectives on social attachment and love

Sue Carter, C. (1998) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(98)00055-9 · Cited by 1,425

Positron Emission Tomographic Analysis of Central D1 and D2 Dopamine Receptor Occupancy in Patients Treated With Classical Neuroleptics and Clozapine: Relation to Extrapyramidal Side Effects

Farde, L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820070032005 · Cited by 1,419

Clozapine Treatment for Suicidality in Schizophrenia<subtitle>International Suicide Prevention Trial (InterSePT)</subtitle>

Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393

Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values.

Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,349

Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison

Pantelis, C., Velakoulis, D., McGorry, P. D., Wood, S. J., Suckling, J., Phillips, L. J., Yung, A. R., Bullmore, E. T., Brewer, W., Soulsby, B., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12323-9 · Cited by 1,310

Oxytocin improves “mind-reading” in humans

Domes, G., Heinrichs, M., Michel, A., Berger, C., & Herpertz, S. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.07.015 · Cited by 1,298

Atypical antipsychotic drugs and the risk of sudden cardiac death

Ray, W. A., Chung, C. P., Murray, K. T., Hall, K., & Stein, C. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806994 · Cited by 1,194

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

Schotte, A., Janssen, P. F. M., Gommeren, W., Luyten, W. H. M. L., Van Gompel, P., Lesage, A. S., De Loore, K., & Leysen, J. E. (1996) · Psychopharmacology · doi:10.1007/bf02245606 · Cited by 1,167

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155

Does Fast Dissociation From the Dopamine D 2 Receptor Explain the Action of Atypical Antipsychotics?: A New Hypothesis

Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140

Randomized Controlled Trial of the Effect on Quality of Life of Second- vs First-Generation Antipsychotic Drugs in Schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)

Jones, P. B., Barnes, T. R. E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R. M., Markwick, A., & Lewis, S. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,105

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

Kahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60486-9 · Cited by 1,088

Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial

Keefe, R. S. E. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.633 · Cited by 1,065

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040

Neuropsychopharmacology: The Fifth Generation of Progress

SAGDUYU, K. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.7.1251-a · Cited by 1,019

Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment

McEvoy, J. P., Lieberman, J. A., Stroup, T. S., Davis, S. M., Meltzer, H. Y., Rosenheck, R. A., Swartz, M. S., Perkins, D. O., Keefe, R. S. E., Davis, C. E., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.600 · Cited by 1,018

Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats

Moghaddam, B., & Adams, B. W. (1998) · Science · doi:10.1126/science.281.5381.1349 · Cited by 1,006

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988

An Akt/β-Arrestin 2/PP2A Signaling Complex Mediates Dopaminergic Neurotransmission and Behavior

Beaulieu, J.-M., Sotnikova, T. D., Marion, S., Lefkowitz, R. J., Gainetdinov, R. R., & Caron, M. G. (2005) · Cell · doi:10.1016/j.cell.2005.05.012 · Cited by 980

Long-term Antipsychotic Treatment and Brain Volumes: A Longitudinal Study of First-Episode Schizophrenia

Ho, B.-C., Andreasen, N. C., Ziebell, S., Pierson, R., & Magnotta, V. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.199 · Cited by 971

Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology

Shapiro, D. A., Renock, S., Arrington, E., Chiodo, L. A., Liu, L.-X., Sibley, D. R., Roth, B. L., & Mailman, R. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300203 · Cited by 968

OXYTOCIN MAY MEDIATE THE BENEFITS OF POSITIVE SOCIAL INTERACTION AND EMOTIONS1The purpose of this paper is to describe the neuroendocrine mechanisms of positive social interactions.1

Uvnäs-Moberg, K. (1998) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(98)00056-0 · Cited by 966

Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders.

Guastella, A. J., Einfeld, S. L., Gray, K. M., Rinehart, N. J., Tonge, B. J., Lambert, T. J., & Hickie, I. B. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.020 · Cited by 962

Atypical antipsychotics: Mechanism of action

Seeman, P. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700106 · Cited by 899

Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders: A Randomized, Placebo-Controlled Trial

Amminger, G. P., Schäfer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., Mackinnon, A., McGorry, P. D., & Berger, G. E. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.192 · Cited by 896

Review: Suicide and schizophrenia: a systematic review of rates and risk factors

Hor, K., & Taylor, M. (2010) · Journal of Psychopharmacology · doi:10.1177/1359786810385490 · Cited by 853

Antipsychotic Drugs: Prolonged QTc Interval, Torsade de Pointes, and Sudden Death

Glassman, A. H., & Bigger, J. T. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1774 · Cited by 822

D1 receptors in prefrontal cells and circuits

Goldman-Rakic, P. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00045-4 · Cited by 807

Antipsychotic Drug Effects on Brain Morphology in First-Episode Psychosis

Lieberman, J. A. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.4.361 · Cited by 801

Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS)

Maninger, N., Wolkowitz, O. M., Reus, V. I., Epel, E. S., & Mellon, S. H. (2009) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2008.11.002 · Cited by 769

Neuropsychopharmacology : The Fifth Generation of Progress

Davis, K. L., Charney, D. S., Coyle, J. T., & Nemeroff, C. B. (2002) · Lippincott Williams & Wilkins eBooks · Cited by 747

Prefrontal neurons and the genetics of schizophrenia

Weinberger, D. R., Egan, M. F., Bertolino, A., Callicott, J. H., Mattay, V. S., Lipska, B. K., Berman, K. F., & Goldberg, T. E. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01252-5 · Cited by 741

Clinical and Theoretical Implications of 5-HT2 and D2 Receptor Occupancy of Clozapine, Risperidone, and Olanzapine in Schizophrenia

Kapur, S., Zipursky, R. B., & Remington, G. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.2.286 · Cited by 712

Omega-3 Fatty Acids: Evidence Basis for Treatment and Future Research in Psychiatry

Freeman, M. P., Hibbeln, J. R., Wisner, K. L., Davis, J. M., Mischoulon, D., Peet, M., Keck, P. E., Marangell, L. B., Richardson, A. J., Lake, J., et al. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1217 · Cited by 709

Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis

Rummel-Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C. A., Kissling, W., Davis, J. M., & Leucht, S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.07.012 · Cited by 675

D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia

Tsai, G. E., Yang, P., Chang, Y.-C., & Chong, M.-Y. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.032 · Cited by 674

Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission

Alex, K. D., & Pehek, E. A. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.08.004 · Cited by 658

Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives

Rupprecht, R., & Holsboer, F. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(99)01399-5 · Cited by 633

Effectiveness of Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: A Review and Meta-Analysis of Randomized Trials

Chakos, M., Lieberman, J., Hoffman, E., Bradford, D., & Sheitman, B. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.4.518 · Cited by 631

Antipsychotic Drug Use and Mortality in Older Adults with Dementia

Gill, S. S., Bronskill, S. E., Normand, S.-L. T., Anderson, G. M., Sykora, K., Lam, K., Bell, C. M., Lee, P. E., Fischer, H. D., Herrmann, N., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-11-200706050-00006 · Cited by 624

Studies of Cognitive Change in Patients With Schizophrenia Following Novel Antipsychotic Treatment

Harvey, P. D., & Keefe, R. S. E. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.2.176 · Cited by 620

A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia

Woodward, N. D., Purdon, S. E., Meltzer, H. Y., & Zald, D. H. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114570500516x · Cited by 605

The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches

Lieberman, J. A., Perkins, D., Belger, A., Chakos, M., Jarskog, F., Boteva, K., & Gilmore, J. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01303-8 · Cited by 593

Executive Subprocesses in Working Memory: Relationship to Catechol-O-methyltransferase Val158Met Genotype and Schizophrenia

Goldberg, T. E., Egan, M. F., Gscheidle, T., Coppola, R., Weickert, T., Kolachana, B. S., Goldman, D., & Weinberger, D. R. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.9.889 · Cited by 583

The Glutamatergic Dysfunction Hypothesis for Schizophrenia

Coyle, J. T. (1996) · Harvard Review of Psychiatry · doi:10.3109/10673229609017192 · Cited by 568

Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys

Arnsten, A. F. T., Cai, J. X., Murphy, B. L., & Goldman-Rakic, P. S. (1994) · Psychopharmacology · doi:10.1007/bf02245056 · Cited by 566

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

Shekhar, A., Potter, W. Z., Lightfoot, J., Lienemann, J., Dubé, S., Mallinckrodt, C., Bymaster, F. P., McKinzie, D. L., & Felder, C. C. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.06091591 · Cited by 560

α 2 -Adrenergic Mechanisms in Prefrontal Cortex Associated with Cognitive Decline in Aged Nonhuman Primates

Arnsten, A. F. T., & Goldman-Rakic, P. S. (1985) · Science · doi:10.1126/science.2999977 · Cited by 549

Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction

Goldman-Rakic, P., Castner, S., Svensson, T., Siever, L., & Williams, G. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1793-y · Cited by 544

Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo

Do, K. Q., Trabesinger, A. H., Kirsten‐Krüger, M., Lauer, C. J., Dydak, U., Hell, D., Holsboer, F., Boesiger, P., & Cuénod, M. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00229.x · Cited by 540

Progressive Structural Brain Abnormalities and Their Relationship to Clinical Outcome: A Longitudinal Magnetic Resonance Imaging Study Early in Schizophrenia

Ho, B.-C., Andreasen, N. C., Nopoulos, P., Arndt, S., Magnotta, V., & Flaum, M. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.585 · Cited by 536

N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action

Dean, O., Giorlando, F., & Berk, M. (2011) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.100057 · Cited by 494

Is schizophrenia a neurodegenerative disorder? a clinical and neurobiological perspective

Lieberman, J. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00147-x · Cited by 483

5-HT system and cognition

Meneses, A. (1999) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(99)00067-6 · Cited by 475

Amisulpride, an Unusual “Atypical” Antipsychotic: A Meta-Analysis of Randomized Controlled Trials

Leucht, S., Pitschel-Walz, G., Engel, R. R., & Kissling, W. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.2.180 · Cited by 470

Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.

Janssen, P. A., Niemegeers, C. J., Awouters, F., Schellekens, K. H., Megens, A. A., & Meert, T. F. (1988) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24408-1 · Cited by 468

Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia

Horacek, J., Bubenikova-Valesova, V., Kopecek, M., Palenicek, T., Dockery, C., Mohr, P., & H??schl, C. (2006) · CNS Drugs · doi:10.2165/00023210-200620050-00004 · Cited by 461

Adverse Effects of Atypical Antipsychotics: Differential Risk and Clinical Implications

Haddad, P. M., & Sharma, S. G. (2007) · CNS Drugs · doi:10.2165/00023210-200721110-00004 · Cited by 456

Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4.

Seeman, P. (1992) · PubMed · Cited by 439

Pharmacological Profile of Lurasidone, a Novel Antipsychotic Agent with Potent 5-Hydroxytryptamine 7 (5-HT7) and 5-HT1A Receptor Activity

Ishibashi, T., Horisawa, T., Tokuda, K., Ishiyama, T., Ogasa, M., Tagashira, R., Matsumoto, K., Nishikawa, H., Ueda, Y., Toma, S., et al. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.167346 · Cited by 438

The Influence of Chronic Exposure to Antipsychotic Medications on Brain Size before and after Tissue Fixation: A Comparison of Haloperidol and Olanzapine in Macaque Monkeys

Dorph-Petersen, K.-A., Pierri, J. N., Perel, J. M., Sun, Z., Sampson, A. R., & Lewis, D. A. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300710 · Cited by 437

Depression in Schizophrenia: Perspective in the Era of “Atypical” Antipsychotic Agents

Siris, S. G. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.9.1379 · Cited by 427

Initial phase 2 trial of a nicotinic agonist in schizophrenia

Freedman, R., Olincy, A., Buchanan, R. W., Harris, J. G., Gold, J. M., Johnson, L., Allensworth, D., Guzman-Bonilla, A., Clement, B., Ball, M. P., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07071135 · Cited by 426

Randomized Controlled Trial of Effect of Prescription of Clozapine Versus Other Second-Generation Antipsychotic Drugs in Resistant Schizophrenia

Lewis, S. W., Barnes, T. R. E., Davies, L., Murray, R. M., Dunn, G., Hayhurst, K. P., Markwick, A., Lloyd, H., & Jones, P. B. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj067 · Cited by 422

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments

Buchanan, R. W., Javitt, D. C., Marder, S. R., Schooler, N. R., Gold, J. M., McMahon, R. P., Heresco-Levy, U., & Carpenter, W. T. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06081358 · Cited by 419

Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug

Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., Moreira, F. A., & Guimarães, F. S. (2006) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2006000400001 · Cited by 402

Brain Volume Changes in First-Episode Schizophrenia: A 1-Year Follow-up Study

Cahn, W., Pol, H. E. H., Lems, E. B. T. E., van Haren, N. E. M., Schnack, H. G., van der Linden, J. A., Schothorst, P. F., van Engeland, H., & Kahn, R. S. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.11.1002 · Cited by 400

A Positron Emission Tomography Study of Quetiapine in Schizophrenia: A Preliminary Finding of an Antipsychotic Effect With Only Transiently High Dopamine D2 Receptor Occupancy

Kapur, S. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.6.553 · Cited by 396

The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes

Arnsten, A., Cai, J., & Goldman-Rakic, P. (1988) · The Journal of Neuroscience · doi:10.1523/jneurosci.08-11-04287.1988 · Cited by 391

Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient

Kapur, S., & Remington, G. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01251-3 · Cited by 390

A Double-Blind, Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase Schizophrenia

Levkovitz, Y., Mendlovich, S., Riwkes, S., Braw, Y., Levkovitch-Verbin, H., Gal, G., Fennig, S., Treves, I., & Kron, S. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04666yel · Cited by 387

Glutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients

Lavoie, S., Murray, M. M., Deppen, P., Knyazeva, M. G., Berk, M., Boulat, O., Bovet, P., Bush, A. I., Conus, P., Copolov, D., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301624 · Cited by 371

Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist–Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile

Kiss, B., Horváth, A., Némethy, Z., Schmidt, É., Laszlovszky, I., Bugovics, G., Fazekas, K., Hornok, K., Orosz, S., Gyertyán, I., et al. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.160432 · Cited by 367

Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients

Schneeweiss, S., Setoguchi, S., Brookhart, A., Dormuth, C., & Wang, P. S. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.061250 · Cited by 366

Management of treatment resistance in schizophrenia

Conley, R. R., & Kelly, D. L. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01271-9 · Cited by 352

Atypical Antipsychotic Agents in the Treatment of Violent Patients With Schizophrenia and Schizoaffective Disorder

Krakowski, M. I., Czobor, P., Citrome, L., Bark, N., & Cooper, T. B. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.6.622 · Cited by 352

Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research

Arranz, M. J., & de Leon, J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002009 · Cited by 351

Glycine transporter I inhibitor, N-Methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia

Tsai, G., Lane, H.-Y., Yang, P., Chong, M.-Y., & Lange, N. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.09.012 · Cited by 342

Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia

Martin, L., Kem, W., & Freedman, R. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1750-1 · Cited by 342

Dopamine Partial Agonists: A New Class of Antipsychotic

Lieberman, J. A. (2004) · CNS Drugs · doi:10.2165/00023210-200418040-00005 · Cited by 340

Immunohistochemical localization of PDE10A in the rat brain

Seeger, T. F., Bartlett, B., Coskran, T. M., Culp, J. S., James, L. C., Krull, D. L., Lanfear, J., Ryan, A. M., Schmidt, C. J., Strick, C. A., et al. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02754-9 · Cited by 334

Free d-aspartate and d-serine in the mammalian brain and periphery

Hashimoto, A., & Oka, T. (1997) · Progress in Neurobiology · doi:10.1016/s0301-0082(97)00019-1 · Cited by 330

Placebo-Controlled Evaluation of Four Novel Compounds for the Treatment of Schizophrenia and Schizoaffective Disorder

Meltzer, H. Y., Arvanitis, L., Bauer, D., Rein, W., & Meta-Trial Study Group (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.6.975 · Cited by 330

Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia

Fenton, W. S., Hibbeln, J., & Knable, M. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00092-x · Cited by 328

Antagonism of dopamine D2 receptor/β-arrestin 2 interaction is a common property of clinically effective antipsychotics

Masri, B., Salahpour, A., Didriksen, M., Ghisi, V., Beaulieu, J.-M., Gainetdinov, R. R., & Caron, M. G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803522105 · Cited by 320

Cognitive Effects of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: A Randomized, Open-Label Clinical Trial (EUFEST)

Davidson, M., Galderisi, S., Weiser, M., Werbeloff, N., Fleischhacker, W. W., Keefe, R. S., Boter, H., Keet, I. P. M., Prelipceanu, D., Rybakowski, J. K., et al. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08060806 · Cited by 320

The Glycine Site on the NMDA Receptor: Structure-Activity Relationships and Therapeutic Potential

Leeson, P. D., & Iversen, L. L. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00050a001 · Cited by 315

Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol

Keefe, R. S. E., Seidman, L. J., Christensen, B. K., Hamer, R. M., Sharma, T., Sitskoorn, M. M., Lewine, R. R. J., Yurgelun-Todd, D. A., Gur, R. C., Tohen, M., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.6.985 · Cited by 314

Overlap of dopaminergic, adrenergic, and serotoninergic receptors and complementarity of their subtypes in primate prefrontal cortex

Goldman-Rakic, P., Lidow, M., & Gallager, D. (1990) · The Journal of Neuroscience · doi:10.1523/jneurosci.10-07-02125.1990 · Cited by 312

Focal Gray Matter Changes in Schizophrenia across the Course of the Illness: A 5-Year Follow-Up Study

van Haren, N. E. M., Hulshoff Pol, H. E., Schnack, H. G., Cahn, W., Mandl, R. C. W., Collins, D. L., Evans, A. C., & Kahn, R. S. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301347 · Cited by 311

A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book

Mishara, A. L., & Goldberg, T. E. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.01.027 · Cited by 310

Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients

Feifel, D., Macdonald, K., Nguyen, A., Cobb, P., Warlan, H., Galangue, B., Minassian, A., Becker, O., Cooper, J., Perry, W., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.04.039 · Cited by 308

Antipsychotic Drugs: A New Risk Factor for Osteoporosis in Young Women With Schizophrenia?

O'Keane, V., & Meaney, A. M. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000150223.31007.e0 · Cited by 307

Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic

Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Swartz, M. S., Davis, S. M., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, C. E., Severe, J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.611 · Cited by 306

Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia

Pedersen, C. A., Gibson, C. M., Rau, S. W., Salimi, K., Smedley, K. L., Casey, R. L., Leserman, J., Jarskog, L. F., & Penn, D. L. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.07.027 · Cited by 305

Intervention in Individuals at Ultra-High Risk for Psychosis: A Review and Future Directions

McGorry, P. D., Nelson, B., Amminger, G. P., Bechdolf, A., Francey, S. M., Berger, G., Riecher-Rössler, A., Klosterkötter, J., Ruhrmann, S., Schultze-Lutter, F., et al. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08r04472 · Cited by 305

A role for the 5-HT1A, 5-HT4 and 5-HT6 receptors in learning and memory

KING, M., MARSDEN, C., & FONE, K. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.07.001 · Cited by 304

A Novel Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Has in Vivo Activity and Antipsychotic-Like Effects in Rat Behavioral Models

Kinney, G. G., O’Brien, J. A., Lemaire, W., Burno, M., Bickel, D. J., Clements, M. K., Chen, T.-B., Wisnoski, D. D., Lindsley, C. W., Tiller, P. R., et al. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.079244 · Cited by 298

The histamine H3receptor: an attractive target for the treatment of cognitive disorders

Esbenshade, T. A., Browman, K. E., Bitner, R. S., Strakhova, M., Cowart, M. D., & Brioni, J. D. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.147 · Cited by 296

Subunit-Selective Modulation of GABA Type A Receptor Neurotransmission and Cognition in Schizophrenia

Lewis, D. A., Cho, R. Y., Carter, C. S., Eklund, K., Forster, S., Kelly, M. A., & Montrose, D. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030395 · Cited by 292

Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial

AKHONDZADEH, S., TABATABAEE, M., AMINI, H., AHMADIABHARI, S., ABBASI, S., & BEHNAM, B. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2006.11.016 · Cited by 289

Blonanserin: A Review of its Use in the Management of Schizophrenia

Deeks, E. D., & Keating, G. M. (2010) · CNS Drugs · doi:10.2165/11202620-000000000-00000 · Cited by 289

Improving the Treatment of Schizophrenia: Focus on Serotonin (5-HT)1A Receptors

Millan, M. J. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38982-7 · Cited by 287

5-HT1A and 5-HT2A Receptor mRNAs and Binding Site Densities Are Differentially Altered in Schizophrenia

Burnet, P. (1996) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00053-x · Cited by 286

Dose-Dependent Effects of the Dopamine D1 Receptor Agonists A77636 or SKF81297 On Spatial Working Memory in Aged Monkeys

Cai, J. X., & Arnsten, A. F. T. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36983-6 · Cited by 285

Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo

Abbas, A. I., Hedlund, P. B., Huang, X.-P., Tran, T. B., Meltzer, H. Y., & Roth, B. L. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1521-8 · Cited by 285

World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia

Tandon, R., Belmaker, R. H., Gattaz, W. F., Lopez-Ibor, J. J., Okasha, A., Singh, B., Stein, D. J., Olie, J.-P., Fleischhacker, W. W., & Moeller, H.-J. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.11.033 · Cited by 276

Prospects for Minocycline Neuroprotection

Plane, J. M., Shen, Y., Pleasure, D. E., & Deng, W. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.191 · Cited by 276

Cognitive Neuroscience-Based Approaches to Measuring and Improving Treatment Effects on Cognition in Schizophrenia: The CNTRICS Initiative

Carter, C. S., & Barch, D. M. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm081 · Cited by 274

Sarcosine or D-Serine Add-on Treatment for Acute Exacerbation of Schizophrenia: A Randomized, Double-blind, Placebo-Controlled Study

Lane, H.-Y., Chang, Y.-C., Liu, Y.-C., Chiu, C.-C., & Tsai, G. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.11.1196 · Cited by 271

Strategies to Enhance N-Methyl-D-Aspartate Receptor-Mediated Neurotransmission in Schizophrenia, a Critical Review and Meta-Analysis

Tsai, G., & Lin, P.-Y. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790361452 · Cited by 269

Phosphodiesterase 10A Inhibitor Activity in Preclinical Models of the Positive, Cognitive, and Negative Symptoms of Schizophrenia

Grauer, S. M., Pulito, V. L., Navarra, R. L., Kelly, M. P., Kelley, C., Graf, R., Langen, B., Logue, S., Brennan, J., Jiang, L., et al. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.155994 · Cited by 269

Effect of Chronic Antipsychotic Exposure on Astrocyte and Oligodendrocyte Numbers in Macaque Monkeys

Konopaske, G. T., Dorph-Petersen, K.-A., Sweet, R. A., Pierri, J. N., Zhang, W., Sampson, A. R., & Lewis, D. A. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.08.018 · Cited by 259

Omega-3 Fatty Acids in the Treatment of Psychiatric Disorders

Peet, M., & Stokes, C. (2005) · Drugs · doi:10.2165/00003495-200565080-00002 · Cited by 258

Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin

Ehrenreich, H., Hinze-Selch, D., Stawicki, S., Aust, C., Knolle-Veentjer, S., Wilms, S., Heinz, G., Erdag, S., Jahn, H., Degner, D., et al. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001907 · Cited by 258

Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders

Roth, B., Hanizavareh, S. M., & Blum, A. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1683-8 · Cited by 257

A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia

Kinon, B. J., Zhang, L., Millen, B. A., Osuntokun, O. O., Williams, J. E., Kollack-Walker, S., Jackson, K., Kryzhanovskaya, L., & Jarkova, N. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318218dcd5 · Cited by 256

Estrogen in Severe Mental Illness: A Potential New Treatment Approach

Kulkarni, J., de Castella, A., Fitzgerald, P. B., Gurvich, C. T., Bailey, M., Bartholomeusz, C., & Burger, H. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.8.955 · Cited by 254

Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment

Müller, N., Krause, D., Dehning, S., Musil, R., Schennach-Wolff, R., Obermeier, M., Möller, H.-J., Klauss, V., Schwarz, M. J., & Riedel, M. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.04.015 · Cited by 250

Tolcapone improves cognition and cortical information processing in normal human subjects

Apud, J. A., Mattay, V., Chen, J., Kolachana, B. S., Callicott, J. H., Rasetti, R., Alce, G., Iudicello, J. E., Akbar, N., Egan, M. F., et al. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301227 · Cited by 242

SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models

Hirst, W. D., Stean, T. O., Rogers, D. C., Sunter, D., Pugh, P., Moss, S. F., Bromidge, S. M., Riley, G., Smith, D. R., Bartlett, S., et al. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.09.049 · Cited by 234

Effect of second-generation antipsychotics on cognition: current issues and future challenges

Hill, S. K., Bishop, J. R., Palumbo, D., & Sweeney, J. A. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.143 · Cited by 233

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment

Lewis, S., Davies, L., Jones, P., Barnes, T., Murray, R., Kerwin, R., Taylor, D., Hayhurst, K., Markwick, A., Lloyd, H., et al. (2006) · Health Technology Assessment · doi:10.3310/hta10170 · Cited by 233

Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system

Emrich, H. M., Leweke, F. M., & Schneider, U. (1997) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(96)00426-1 · Cited by 226

Estrogen — a potential treatment for schizophrenia

Kulkarni, J., Riedel, A., de Castella, A. R., Fitzgerald, P. B., Rolfe, T. J., Taffe, J., & Burger, H. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00088-8 · Cited by 225

Molecular Targets for Treating Cognitive Dysfunction in Schizophrenia

Gray, J. A., & Roth, B. L. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm074 · Cited by 225

Therapeutic Potential of Erythropoietin and its Structural or Functional Variants in the Nervous System

Sirén, A.-L., Faßhauer, T., Bartels, C., & Ehrenreich, H. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.041 · Cited by 222

N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives

Millan, M. J. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2199-1 · Cited by 221

Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection

Lieberman, J. A., Bymaster, F. P., Meltzer, H. Y., Deutch, A. Y., Duncan, G. E., Marx, C. E., Aprille, J. R., Dwyer, D. S., Li, X.-M., Mahadik, S. P., et al. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.00107 · Cited by 220

Neuro-Psychopharmacology

Marley, E. (1962) · Psychopharmacologia · doi:10.1007/bf00411372 · Cited by 218

Pharmacological treatment of primary negative symptoms in schizophrenia: A systematic review

Murphy, B. P., Chung, Y.-C., Park, T.-W., & McGorry, P. D. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.07.002 · Cited by 217

Neuronal nicotinic receptors: A perspective on two decades of drug discovery research

Arneric, S. P., Holladay, M., & Williams, M. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.06.033 · Cited by 208

Erythropoietin: a candidate compound for neuroprotection in schizophrenia

Ehrenreich, H., Degner, D., Meller, J., Brines, M., Béhé, M., Hasselblatt, M., Woldt, H., Falkai, P., Knerlich, F., Jacob, S., et al. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001442 · Cited by 208

Enhancement of Cognitive Performance in Schizophrenia by Addition of Tandospirone to Neuroleptic Treatment

Sumiyoshi, T., Matsui, M., Nohara, S., Yamashita, I., Kurachi, M., Sumiyoshi, C., Jayathilake, K., & Meltzer, H. Y. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.10.1722 · Cited by 207

The Evolution of Drug Development in Schizophrenia: Past Issues and Future Opportunities

Carpenter, W. T., & Koenig, J. I. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301639 · Cited by 206

Serotonergic basis of antipsychotic drug effects in schizophrenia

Lieberman, J. A., Mailman, R. B., Duncan, G., Sikich, L., Chakos, M., Nichols, D. E., & Kraus, J. E. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00187-5 · Cited by 206

Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia

Swanson, J. W., Swartz, M. S., Van Dorn, R. A., Volavka, J., Monahan, J., Stroup, T. S., McEvoy, J. P., Wagner, H. R., Elbogen, E. B., & Lieberman, J. A. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.042630 · Cited by 205

5-Hydroxytryptamine2A Receptor Inverse Agonists as Antipsychotics

Weiner, D. M., Burstein, E. S., Nash, N., Croston, G. E., Currier, E. A., Vanover, K. E., Harvey, S. C., Donohue, E., Hansen, H. C., Andersson, C. M., et al. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29327-7 · Cited by 203

Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release

Gobert, A., Rivet, J.-M., Audinot, V, Newman-Tancredi, A., Cistarelli, L., & Millan, M. J. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00565-4 · Cited by 203

The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone

Green, M. F., Marder, S. R., Glynn, S. M., McGurk, S. R., Wirshing, W. C., Wirshing, D. A., Liberman, R. P., & Mintz, J. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01370-7 · Cited by 202

Dehydroepiandrosterone Augmentation in the Management of Negative, Depressive, and Anxiety Symptoms in Schizophrenia

Strous, R. D., Maayan, R., Lapidus, R., Stryjer, R., Lustig, M., Kotler, M., & Weizman, A. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.2.133 · Cited by 201

Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia

Konradi, C., & Heckers, S. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01267-7 · Cited by 200

Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol on Hostility Among Patients With Schizophrenia

Citrome, L., Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, J.-P., McEvoy, J., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2001) · Psychiatric Services · doi:10.1176/appi.ps.52.11.1510 · Cited by 200

The Effects of a Selective D4 Dopamine Receptor Antagonist (L-745,870) in Acutely Psychotic Inpatients With Schizophrenia

Kramer, M. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830180085011 · Cited by 199

Social Interaction Deficits Caused by Chronic Phencyclidine Administration are Reversed by Oxytocin

Lee, P. R., Brady, D. L., Shapiro, R. A., Dorsa, D. M., & Koenig, J. I. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300722 · Cited by 199

Glutathione and Signal Transduction in the Mammalian CNS

Janáky, R., Ogita, K., Pasqualotto, B. A., Bains, J. S., Oja, S. S., Yoneda, Y., & Shaw, C. A. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0730889.x · Cited by 194

Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia

Marx, C. E., Keefe, R. S. E., Buchanan, R. W., Hamer, R. M., Kilts, J. D., Bradford, D. W., Strauss, J. L., Naylor, J. C., Payne, V. M., Lieberman, J. A., et al. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.26 · Cited by 193

Effect of Chronic Exposure to Antipsychotic Medication on Cell Numbers in the Parietal Cortex of Macaque Monkeys

Konopaske, G. T., Dorph-Petersen, K.-A., Pierri, J. N., Wu, Q., Sampson, A. R., & Lewis, D. A. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301233 · Cited by 192

Thymosthenic effects of ritanserin (R 55667), a centrally acting serotonin‐S2 receptor blocker

Reyntjens, A., Gelders, Y. G., Hoppenbrouwers, M. J. A., & Vanden Bussche, G. (1986) · Drug Development Research · doi:10.1002/ddr.430080124 · Cited by 192

Possible implications of the dopamine D3 receptor in schizophrenia and in antipsychotic drug actions

Schwartz, J. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00043-0 · Cited by 191

First onset and early symptomatology of schizophrenia: A chapter of epidemiological and neurobiological research into age and sex differences

Häfner, H., Riecher-Rössler, A., Maurer, K., Fätkenheuer, B., & Löffler, W. (1992) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02191557 · Cited by 190

The pipeline and future of drug development in schizophrenia

Gray, J. A., & Roth, B. L. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002062 · Cited by 184

A Placebo-Controlled Add-On Trial of the Ampakine, CX516, for Cognitive Deficits in Schizophrenia

Goff, D. C., Lamberti, J. S., Leon, A. C., Green, M. F., Miller, A. L., Patel, J., Manschreck, T., Freudenreich, O., & Johnson, S. A. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301444 · Cited by 182

ADX47273 [S-(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: A Novel Metabotropic Glutamate Receptor 5-Selective Positive Allosteric Modulator with Preclinical Antipsychotic-Like and Procognitive Activities

Liu, F., Grauer, S., Kelley, C., Navarra, R., Graf, R., Zhang, G., Atkinson, P. J., Popiolek, M., Wantuch, C., Khawaja, X., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.136580 · Cited by 182

Glycine Transporter I Inhibitor, N-methylglycine (Sarcosine), Added to Clozapine for the Treatment of Schizophrenia

Lane, H.-Y., Huang, C.-L., Wu, P.-L., Liu, Y.-C., Chang, Y.-C., Lin, P.-Y., Chen, P.-W., & Tsai, G. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.04.005 · Cited by 179

A randomized, double-blind, placebo-controlled comparison study of sarcosine ( N-methylglycine) and d-serine add-on treatment for schizophrenia

Lane, H.-Y., Lin, C.-H., Huang, Y.-J., Liao, C.-H., Chang, Y.-C., & Tsai, G. E. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990939 · Cited by 179

Pharmacologic treatment of schizophrenia

Kane, J. M., & Correll, C. U. (2010) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2010.12.3/jkane · Cited by 176

A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia

Buchanan, R. W., Keefe, R. S. E., Lieberman, J. A., Barch, D. M., Csernansky, J. G., Goff, D. C., Gold, J. M., Green, M. F., Jarskog, L. F., Javitt, D. C., et al. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.09.052 · Cited by 172

Extrastriatal and striatal D2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia

Xiberas, X., Martinot, J. L., Mallet, L., Artiges, E., Loc'h, C., Mazière, B., & Paillère-Martinot, M. L. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.6.503 · Cited by 171

Galantamine for the treatment of cognitive impairments in people with schizophrenia

Buchanan, R. W., Conley, R. R., Dickinson, D., Ball, M. P., Feldman, S., Gold, J. M., & McMahon, R. P. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07050724 · Cited by 170

Recent Advances in the Development of Novel Pharmacological Agents for the Treatment of Cognitive Impairments in Schizophrenia

Buchanan, R. W., Freedman, R., Javitt, D. C., Abi-Dargham, A., & Lieberman, J. A. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm083 · Cited by 169

Neuroactive Steroids are Altered in Schizophrenia and Bipolar Disorder: Relevance to Pathophysiology and Therapeutics

Marx, C. E., Stevens, R. D., Shampine, L. J., Uzunova, V., Trost, W. T., Butterfield, M. I., Massing, M. W., Hamer, R. M., Morrow, A. L., & Lieberman, J. A. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300952 · Cited by 165

Sarcosine (N-Methylglycine) Treatment for Acute Schizophrenia: A Randomized, Double-Blind Study

Lane, H.-Y., Liu, Y.-C., Huang, C.-L., Chang, Y.-C., Liau, C.-H., Perng, C.-H., & Tsai, G. E. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.04.038 · Cited by 164

An animal model for the effects of estradiol on dopamine-mediated behavior: Implications for sex differences in schizophrenia

Häfner, H., Behrens, S., De Vry, J., & Gattaz, W. F. (1991) · Psychiatry Research · doi:10.1016/0165-1781(91)90038-q · Cited by 161

Heterogeneity of violence in schizophrenia and implications for long-term treatment

Volavka, J., & Citrome, L. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01797.x · Cited by 160

Omega-3 fatty acids: potential role in the management of early Alzheimer’s disease

Jicha, G. A., & Markesbery, W. R. (2010) · Clinical Interventions in Aging · doi:10.2147/cia.s5231 · Cited by 160

Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine

Zhang, L., Kitaichi, K., Fujimoto, Y., Nakayama, H., Shimizu, E., Iyo, M., & Hashimoto, K. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.05.015 · Cited by 159

One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia

Keefe, R. S. E., Young, C. A., Rock, S. L., Purdon, S. E., Gold, J. M., & Breier, A. F. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.038 · Cited by 159

Substance abuse and schizophrenia: Pharmacotherapeutic intervention

Green, A. I., Noordsy, D. L., Brunette, M. F., & O’Keefe, C. D. (2007) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2007.01.008 · Cited by 157

Pharmacologic treatment of schizophrenia

Kane, J. M. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00059-1 · Cited by 156

Ritanserin, a Selective 5-HT2/1CAntagonist, and Negative Symptoms in Schizophrenia: A Placebo-Controlled Double-Blind Trial

Duinkerke, S. J., Botter, P. A., Jansen, A. A. I., van Dongen, P. A. M., Haaften, A. J. V., Boom, A. J., Laarhoven, J. H. M. V., & Busard, H. L. S. M. (1993) · The British Journal of Psychiatry · doi:10.1192/bjp.163.4.451 · Cited by 156

Risk of torsades de pointes with non-cardiac drugs

Yap, Y. G. (2000) · BMJ · doi:10.1136/bmj.320.7243.1158 · Cited by 155

Facilitative Effects of the Ampakine CX516 on Short-Term Memory in Rats: Enhancement of Delayed-Nonmatch-to-Sample Performance

Hampson, R. E., Rogers, G. A., LYNCH, G. S., & Deadwyler, S. A. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-07-02740.1998 · Cited by 152

The American Psychiatric Press Textbook of Psychopharmacology

Schatzberg, A. F., & Nemeroff, C. B. (1995) · Medical Entomology and Zoology · Cited by 150

The role of norepinephrine in the pathophysiology of cognitive disorders: potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease

Friedman, J. I., Adler, D. N., & Davis, K. L. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00232-2 · Cited by 149

Lack of apparent antipsychotic effect of the D1-dopamine recepotr antagonist SCH39166 in acutely ill schizophrenic patients

Karlsson, P., Farde, L., Härnryd, C., Sedvall, G., Smith, L. A., & Wiesel, F. ‐. (1995) · Psychopharmacology · doi:10.1007/bf02246068 · Cited by 149

Glycine transporters: essential regulators of synaptic transmission

Betz, H., Gomeza, J., Armsen, W., Scholze, P., & Eulenburg, V. (2006) · Biochemical Society Transactions · doi:10.1042/bst0340055 · Cited by 148

Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: A randomized, double-blind, placebo-controlled study

Sumiyoshi, T., Park, S., Jayathilake, K., Roy, A., Ertuğrul, A., & Meltzer, H. Y. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.06.008 · Cited by 147

WAY-163909 [(7 bR,10 aR)-1,2,3,4,8,9,10,10 a-Octahydro-7 bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A Novel 5-Hydroxytryptamine 2C Receptor-Selective Agonist with Preclinical Antipsychotic-Like Activity

Marquis, K. L., Sabb, A. L., Logue, S. F., Brennan, J. A., Piesla, M. J., Comery, T. A., Grauer, S. M., Ashby, C. R., Nguyen, H. Q., Dawson, L. A., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.106989 · Cited by 146

Exacerbation of Schizophrenia by Varenicline

Freedman, R. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07020326 · Cited by 145

Polyunsaturated fatty acid supplementation for schizophrenia

Irving, C. B., Mumby-Croft, R., & Joy, L. A. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001257.pub2 · Cited by 143

TC-5619: An alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia

Hauser, T. A., Kucinski, A. J., Green-Jordan, K., Gatto, G. J., Wersinger, S. R., Hesse, R. A., Stachowiak, E. K., Stachowiak, M. K., Papke, R. L., Lippiello, P. M., et al. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.05.030 · Cited by 143

Variation in symptom severity over the menstrual cycle of Schizophrenics

Hallonquist, J. D., Seeman, M. V., Lang, M., & Rector, N. A. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90141-y · Cited by 141

Galantamine Improves Cognition in Schizophrenic Patients Stabilized on Risperidone

Schubert, M., Young, K. A., & Hicks, P. B. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.04.006 · Cited by 140

Schizophrenia

Owen, M. J., Sawa, A., & Mortensen, P. B. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01121-6 · Cited by 1,870

Gut instincts: microbiota as a key regulator of brain development, ageing and neurodegeneration

Dinan, T. G., & Cryan, J. F. (2017) · The Journal of Physiology · doi:10.1113/jp273106 · Cited by 813

Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial

McGuire, P., Robson, P., Cubala, W. J., Vasile, D., Morrison, P. D., Barron, R., Taylor, A., & Wright, S. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17030325 · Cited by 617

Polypharmacology – Foe or Friend?

Peters, J.-U. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400856t · Cited by 465

Trace Amines and Their Receptors

Gainetdinov, R. R., Hoener, M. C., & Berry, M. D. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015305 · Cited by 384